PT  - JOURNAL ARTICLE
AU  - Gill, N.
AU  - Gniadecki, R.
TI  - Incidence and Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis
AID  - 10.1101/19012559
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19012559
4099  - http://medrxiv.org/content/early/2019/11/22/19012559.short
4100  - http://medrxiv.org/content/early/2019/11/22/19012559.full
AB  - Background Hidradenitis is a chronic relapsing follicular occlusive disease with a widely variable reported prevalence. The exact prevalence and incidence of HS is unknown.Objectives To perform a systematic review and meta-analysis of the published literature to estimate the global incidence and prevalence of HS.Methods Literature searches were performed on Medline, Embase, and Pubmed to identify studies reporting incidence and/or prevalence of HS. Pooled estimates of prevalence and incidence were calculated with a meta-analysis of proportions.Results In total, 12 studies were included (Australia, Brazil, Denmark, France, Germany, Ireland, Israel, UK, USA) comprising a total population of 53,805,690. Eleven studies reported prevalence. The pooled proportion of individuals in the general population with HS was 0.36% (95% CI 0.21 - 0.56). Self-reported HS gave a higher prevalence estimate than clinician-diagnosed HS. HS is more prevalent in women. Average annual incidence of HS was 28.5 cases/100,000 (95% CI 26.8 – 30.1).Conclusions We estimated the global prevalence of HS to be 0.36% with 3:2 female predominance and average annual incidence to be 28.5 cases/100,000.Competing Interest StatementR.G. has received speaker's honoraria from Mallinckrodt, Janssen, AbbVie, Novartis and LEO Pharma; is on advisory boards for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lilly, Sanofi, Novartis and LEO Pharma; and is an investigator in clinical trials for Janssen, Celgene, AbbVie and LEO Pharma. N.G. has no conflicts of interest to declare.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIncluded in Table 1